MIC Breakpoints for Piperacillin-Tazobactam Against Proteus mirabilis
The FDA-recognized susceptibility breakpoint for piperacillin-tazobactam against Proteus mirabilis is ≤16/4 mg/L (susceptible), with the 2022 CLSI revised breakpoints now defining ≤8/4 mg/L as susceptible, 16/4 mg/L as susceptible dose-dependent (SDD), and ≥32/4 mg/L as resistant. 1, 2
Current FDA-Recognized Breakpoints
The FDA drug label lists Proteus mirabilis among organisms for which ≥90% of isolates exhibit an MIC ≤16/4 mg/L (the susceptible breakpoint), though clinical efficacy has not been established in adequate controlled trials for this specific pathogen. 1
Proteus mirabilis is noted as a non-β-lactamase-producing organism and therefore remains susceptible to piperacillin alone in most cases. 1
2022 CLSI Revised Breakpoints for Enterobacterales
The CLSI revised the piperacillin-tazobactam breakpoints in 2022 to ≤8/4 mg/L (susceptible), 16/4 mg/L (susceptible dose-dependent), and ≥32/4 mg/L (resistant) based on pharmacokinetic/pharmacodynamic modeling, Monte Carlo simulations, and clinical trial safety signals. 2
This revision applies to all Enterobacterales, including Proteus mirabilis, and reflects concerns that isolates with MICs of 16/4 mg/L may require optimized dosing strategies (higher doses or extended infusions) to achieve adequate clinical outcomes. 2
Clinical Context: ESBL-Producing Proteus mirabilis
For ESBL-producing Proteus mirabilis, piperacillin-tazobactam demonstrates variable activity depending on MIC values. 3, 4
In a multicenter study of ESBL-producing Proteus mirabilis bacteremia, 95.6% of isolates were susceptible to piperacillin-tazobactam, with MICs ranging from 0.125 to 16 mg/L. 3
Mortality was significantly lower when piperacillin-tazobactam was used for isolates with MICs ≤0.5/4 mg/L (0% mortality) compared to MICs ≥1/4 mg/L (60% mortality, P=0.045), suggesting that lower MICs within the susceptible range predict better outcomes. 3
Another study of ESBL-producing Enterobacterales bacteremia found that an MIC breakpoint of ≤8/4 mg/L showed significantly higher microbiological and clinical efficacy compared to MICs ≥16/4 mg/L (P<0.05), supporting the 2022 CLSI revision. 5
Dosing Implications Based on MIC
For isolates with MICs ≤8/4 mg/L, standard dosing of 3.375 g every 6 hours or 4.5 g every 8 hours is appropriate. 6
For isolates with MICs of 16/4 mg/L (susceptible dose-dependent), use extended infusions (3–4 hours) or higher doses (4.5 g every 6 hours as a 3-hour infusion) to optimize the probability of achieving 50% fT>MIC. 6, 7, 6
In critically ill patients or those with obesity, extended infusions (4 hours) or continuous infusions are recommended to compensate for increased volume of distribution and clearance, ensuring adequate drug exposure against susceptible pathogens with MICs ≤16 mg/L. 6
Key Caveats
The French Society of Pharmacology and Therapeutics considers MICs >2 mg/L for piperacillin-tazobactam against E. coli as "high MIC," suggesting that similar thresholds may apply to other Enterobacterales like Proteus mirabilis when considering the need for extended or continuous infusions. 7
Carbapenem therapy remains the preferred choice for ESBL-producing Proteus mirabilis bacteremia, particularly when MICs approach or exceed 16/4 mg/L, given the mortality benefit observed in clinical studies. 3
Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis has been documented, where isolates remain susceptible to piperacillin-tazobactam and carbapenems but can become resistant after a single promoter mutation—highlighting the importance of ongoing susceptibility testing. 8